Palvella Therapeutics, Inc.NASDAQ: PVLA

Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations

· Issued by Palvella Therapeutics, Inc.
Watch Palvella Therapeutics explain itPalvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call · Replay · Aug 4

Primary endpoint met with statistically significant improvement (mean change of +2.13; p

Company analysis